Literature DB >> 19968383

Personality, stressful life events, and treatment response in major depression.

Eric Bulmash1, Kate L Harkness, Jeremy G Stewart, R Michael Bagby.   

Abstract

The current study examined whether the personality traits of self-criticism or dependency moderated the effect of stressful life events on treatment response. Depressed outpatients (N = 113) were randomized to 16 weeks of cognitive-behavioral therapy, interpersonal psychotherapy, or antidepressant medication (ADM). Stressful life events were assessed with the Bedford College Life Events and Difficulties Schedule. Severe events reported during or immediately prior to treatment predicted poor response in the ADM condition but not in the psychotherapy conditions. In contrast, nonsevere life events experienced prior to onset predicted superior response to treatment. Further, self-criticism moderated the relation of severe life events to outcome across conditions, such that in the presence of severe stress those high in self-criticism were less likely to respond to treatment than were those low in self-criticism.

Entities:  

Mesh:

Year:  2009        PMID: 19968383     DOI: 10.1037/a0017149

Source DB:  PubMed          Journal:  J Consult Clin Psychol        ISSN: 0022-006X


  12 in total

1.  Comorbid depression and substance use disorder: longitudinal associations between symptoms in a controlled trial.

Authors:  Matthew J Worley; Ryan S Trim; Scott C Roesch; Jennifer Mrnak-Meyer; Susan R Tate; Sandra A Brown
Journal:  J Subst Abuse Treat       Date:  2012-03-08

Review 2.  Gene-environment interaction in major depression and antidepressant treatment response.

Authors:  Robert Keers; Rudolf Uher
Journal:  Curr Psychiatry Rep       Date:  2012-04       Impact factor: 5.285

3. 

Authors:  Daniel C Kopala-Sibley; Gabrielle B Chartier; Shiv Bhanot; Jaeden Cole; Peter Y Chan; Marcelo T Berlim; Alexander McGirr
Journal:  Can J Psychiatry       Date:  2019-05-01       Impact factor: 4.356

4.  Stressful life events, perceived stress, and 12-month course of geriatric depression: direct effects and moderation by the 5-HTTLPR and COMT Val158Met polymorphisms.

Authors:  Anthony S Zannas; Douglas R McQuoid; David C Steffens; George P Chrousos; Warren D Taylor
Journal:  Stress       Date:  2012-01-04       Impact factor: 3.493

5.  Gender differences in life events prior to onset of major depressive disorder: the moderating effect of age.

Authors:  Kate L Harkness; Nazanin Alavi; Scott M Monroe; George M Slavich; Ian H Gotlib; R Michael Bagby
Journal:  J Abnorm Psychol       Date:  2010-11

6.  Do Cognitive Therapy Skills Neutralize Lifetime Stress to Improve Treatment Outcomes in Recurrent Depression?

Authors:  Jeffrey R Vittengl; Sonja Stutzman; Aparna Atluru; Robin B Jarrett
Journal:  Behav Ther       Date:  2019-11-27

7.  Interactions between neuroticism and stressful life events predict response to pharmacotherapy for major depression: A CAN-BIND 1 report.

Authors:  Timothy A Allen; Kate L Harkness; Raymond W Lam; Roumen Milev; Benicio N Frey; Daniel J Mueller; Rudolf Uher; Sidney H Kennedy; Lena C Quilty
Journal:  Personal Ment Health       Date:  2021-05-18

Review 8.  The effectiveness of individual interpersonal psychotherapy as a treatment for major depressive disorder in adult outpatients: a systematic review.

Authors:  Madelon L J M van Hees; Thomas Rotter; Tim Ellermann; Silvia M A A Evers
Journal:  BMC Psychiatry       Date:  2013-01-11       Impact factor: 3.630

Review 9.  Psychotherapeutic benefits of compassion-focused therapy: an early systematic review.

Authors:  J Leaviss; L Uttley
Journal:  Psychol Med       Date:  2014-09-12       Impact factor: 7.723

10.  Treatment response classes in major depressive disorder identified by model-based clustering and validated by clinical prediction models.

Authors:  Riya Paul; Till F M Andlauer; Darina Czamara; David Hoehn; Susanne Lucae; Benno Pütz; Cathryn M Lewis; Rudolf Uher; Bertram Müller-Myhsok; Marcus Ising; Philipp G Sämann
Journal:  Transl Psychiatry       Date:  2019-08-05       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.